Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$107.29

0.04 (0.04%)

12:34
10/09/19
10/09
12:34
10/09/19
12:34

Eli Lilly says Verzenio 'significantly extends life for women in MONARCH 2 study

Eli Lilly and Company announced that Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer previously treated with endocrine therapy. Results from the Phase 3 MONARCH 2 clinical trial, which included both pre/peri- and postmenopausal women, were consistent across subgroups. These results were presented as a late-breaking abstract in the Presidential Symposium, at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain and simultaneously published in JAMA Oncology. "These positive results definitively showed that Verzenio plus fulvestrant reached statistical significance at a pre-planned interim analysis. Lilly will continue to monitor patients enrolled in the trial. Any additional analyses will be considered post-hoc. Lilly plans to submit these overall survival data to global regulatory authorities. Verzenio in combination with fulvestrant is currently approved in more than 50 countries worldwide, including Canada," the company said.

  • 11

    Oct

  • 23

    Oct

LLY Eli Lilly
$107.29

0.04 (0.04%)

07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
09/09/19
PIPR
09/09/19
NO CHANGE
Target $85
PIPR
Neutral
Lilly's 'impressive update' raised bar higher for Blueprint, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he thinks Eli Lilly (LLY) issued an "impressive update" on selpercatinib at the World Lung meeting, raising the bar for Blueprint Medicines' (BPMC) pralsetinib "meaningfully higher." While selpercatinib's "best-in-class" ORR was maintained, initial durability data could be upwards of 50% better than that of pralsetinib, according to Raymond. While cautioning that his comparison is highly preliminary, Raymond said he worries that LOXO-292's superiority gap against pralsetinib "may be widening." He keeps a Neutral rating on Blueprint shares, which are down about 3% in morning trading to $75.89.
09/25/19
PIPR
09/25/19
NO CHANGE
Target $81
PIPR
Overweight
AbbVie survey supports above-consensus estimates, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on AbbVie (ABBV) shares with an $81 price target following a new rheumatologist survey by his firm's partners Spherix Global Insights. The survey indicates "robust" expectations for the company's oral JAK1 inhibitor Rinvoq, Raymond tells investors in a research note. Rheumatologists project that in six months, Rinvoq will leapfrog Eli Lilly's (LLY) Olumiant to become the second-most prescribed JAK with 5% share, says the analyst, citing the survey. He believes this supports his above-consensus Rinvoq revenue estimates.

TODAY'S FREE FLY STORIES

AYTU

Aytu BioScience

$1.21

(0.00%)

09:42
10/14/19
10/14
09:42
10/14/19
09:42
Conference/Events
Aytu BioScience to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

FCX

Freeport McMoRan

$9.54

(0.00%)

, WDC

Western Digital

$58.36

(0.00%)

09:40
10/14/19
10/14
09:40
10/14/19
09:40
Options
Unusually active option classes on open October 14th »

Unusual total active…

FCX

Freeport McMoRan

$9.54

(0.00%)

WDC

Western Digital

$58.36

(0.00%)

ASHR

X-trackers Harvest CSI 300

$28.16

(0.00%)

BYND

Beyond Meat

$131.40

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

FND

Floor & Decor

$48.93

0.69 (1.43%)

09:39
10/14/19
10/14
09:39
10/14/19
09:39
Recommendations
Floor & Decor analyst commentary  »

Floor & Decor price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

BOX

Box

$16.74

0.345 (2.10%)

09:36
10/14/19
10/14
09:36
10/14/19
09:36
Periodicals
Box hires Morgan Stanley as advisor amid activist push, Dealreporter says »

Faced with activist…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

REPR

RMS Medical Products

$0.00

(0.00%)

09:35
10/14/19
10/14
09:35
10/14/19
09:35
Hot Stocks
RMS Medical Products to commence trading on Nasdaq on October 17 »

Repro Med Systems, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

VRTS

Virtus Investment

$90.90

2.59 (2.93%)

09:34
10/14/19
10/14
09:34
10/14/19
09:34
Upgrade
Virtus Investment rating change  »

Virtus Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$62.65

0.46 (0.74%)

09:34
10/14/19
10/14
09:34
10/14/19
09:34
Hot Stocks
Vornado announces certain items to be included in Q3 results »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

CHKP

Check Point

$111.27

1.78 (1.63%)

09:32
10/14/19
10/14
09:32
10/14/19
09:32
Downgrade
Check Point rating change  »

Check Point downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 28

    Oct

  • 16

    Dec

BSMX

Santander Mexico

$6.86

0.165 (2.47%)

09:32
10/14/19
10/14
09:32
10/14/19
09:32
Upgrade
Santander Mexico rating change  »

Santander Mexico upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

09:30
10/14/19
10/14
09:30
10/14/19
09:30
General news
Oil Action: Front-month WIT are down 2.3% »

Oil Action: Front-month…

GM

General Motors

$35.57

0.9 (2.60%)

09:29
10/14/19
10/14
09:29
10/14/19
09:29
Recommendations
General Motors analyst commentary  »

Morgan Stanley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

ACB

Aurora Cannabis

$3.68

-0.045 (-1.21%)

09:28
10/14/19
10/14
09:28
10/14/19
09:28
Recommendations
Aurora Cannabis analyst commentary  »

Aurora Cannabis price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

09:25
10/14/19
10/14
09:25
10/14/19
09:25
General news
Oil Action: Front-month WIT are down 2.3% »

Oil Action: Front-month…

ZLAB

Zai Lab

$32.38

0.01 (0.03%)

09:25
10/14/19
10/14
09:25
10/14/19
09:25
Conference/Events
Zai Lab participates in a conference call with JPMorgan »

SMid Biotechnology Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

09:24
10/14/19
10/14
09:24
10/14/19
09:24
Recommendations
Amazon.com analyst commentary  »

Loop Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

F

Ford

$8.78

0.145 (1.68%)

09:22
10/14/19
10/14
09:22
10/14/19
09:22
Hot Stocks
Ford reports Q3 Europe sales up 3.1% to 313,400 vehicles »

Ford sales grew more than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ACM

Aecom

$37.14

0.35 (0.95%)

, LPG

Dorian LPG

$11.48

0.22 (1.95%)

09:21
10/14/19
10/14
09:21
10/14/19
09:21
Hot Stocks
Fly Intel: Pre-market Movers »

HIGHER: Aecom (ACM), up…

ACM

Aecom

$37.14

0.35 (0.95%)

LPG

Dorian LPG

$11.48

0.22 (1.95%)

LYFT

Lyft

$39.49

1.8 (4.78%)

WDC

Western Digital

$58.36

1.09 (1.90%)

FLXN

Flexion

$13.37

0.125 (0.94%)

AMTD

TD Ameritrade

$35.27

0.78 (2.26%)

IPGP

IPG Photonics

$136.12

6.24 (4.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

YNDX

Yandex

$29.95

-5.62 (-15.80%)

09:19
10/14/19
10/14
09:19
10/14/19
09:19
Recommendations
Yandex analyst commentary  »

Foreign ownership limit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

AMCX

AMC Networks

$48.42

0.89 (1.87%)

09:19
10/14/19
10/14
09:19
10/14/19
09:19
Downgrade
AMC Networks rating change  »

Evercore downgrades AMC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
10/14/19
10/14
09:18
10/14/19
09:18
Options
Overnight activity included 332 trades in SPX and 7 trades in VIX »

332 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

, ABBV

AbbVie

$73.66

1.39 (1.92%)

09:17
10/14/19
10/14
09:17
10/14/19
09:17
Hot Stocks
Allergan shareholders approve AbbVie acquisition proposal »

Allergan (AGN) announced…

AGN

Allergan

$169.06

1.255 (0.75%)

ABBV

AbbVie

$73.66

1.39 (1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

TOL

Toll Brothers

$39.49

0.2 (0.51%)

09:16
10/14/19
10/14
09:16
10/14/19
09:16
Downgrade
Toll Brothers rating change  »

Toll Brothers downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBT

Global Blood Therapeutics

$46.49

0.61 (1.33%)

09:16
10/14/19
10/14
09:16
10/14/19
09:16
Recommendations
Global Blood Therapeutics analyst commentary  »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AMGN

Amgen

$200.76

2.05 (1.03%)

09:15
10/14/19
10/14
09:15
10/14/19
09:15
Initiation
Amgen initiated  »

Amgen resumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

JAZZ

Jazz Pharmaceuticals

$118.61

0.62 (0.53%)

09:13
10/14/19
10/14
09:13
10/14/19
09:13
Initiation
Jazz Pharmaceuticals initiated  »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.